Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

March 11, 2014   6:00 – 8:15 p.m.
*** Please note new times ***

1. Executive Session 6:00 - 6:15
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes 6:15 - 6:20
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:20 - 6:25
   - Updates

4. Medical Director Update 6:25 - 6:30
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:30 – 7:00
   - Oxycodone IR/Hydromorphone IR Retrospective Drug Utilization Review

6. RetroDUR/DUR 7:00 – 7:00
   - No new topics this meeting

7. Therapeutic Drug Classes – Periodic Review 7:00 – 7:10
   (Public comment prior to Board action)
   - Hepatitis C Medications

8. Clinical Update: Drug Reviews 7:10 – 8:05
   (Public comment prior to Board action)
   - New to Market
     - Zohydro® ER (hydrocodone) – update
   - Abbreviated New Drug Reviews
     - Epaned® (enalapril) Oral Solution
     - Esomeprazole® (esomeprazole) Oral Capsule
     - Onfi® (clobazam) Oral Suspension
     - Simponi® (golimumab) IV Infusion (Rheumatoid Arthritis)
     - Simponi® (golimumab) Subcutaneous (100 mg dose for Ulcerative Colitis)
     - Trokendi® XR (topiramate) Extended Release Oral Capsule
Full New Drug Reviews
- Brisdelle® (paroxetine) Oral Capsule
- Mirvaso® (brimonidine) Topical Gel
- Olysio® (simeprevir) Oral Capsule (updated with new AASLD guidelines)
- Sovaldi® (sofosbuvir) Oral Tablet (updated with new AASLD guidelines)

   (Public comment prior to Board action)
   - American Academy of Neurology (AAN) Guidelines on Stroke Prevention in
     Nonvalvular Atrial Fibrillation (NVAF)

10. New Managed Therapeutic Drug Classes 8:10– 8:10
    (Public comment prior to Board action)
    - None

11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:10 – 8:10
    (Public comment prior to Board action)
    - None

12. General Announcements 8:10– 8:15
    Selected FDA Safety Alerts
    - FDA Drug Safety Communication: FDA to review heart failure risk with
      diabetes drug saxagliptin (marketed as Onglyza® and Kombiglyze® XR)
    - FDA evaluating risk of stroke, heart attack and death with FDA-approved
      testosterone products

13. Adjourn 8:15